Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Böhler

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Advances in Cancer Research|January 8, 2013
Therapeutic potential of targeting SK1 in human cancersHeba Alshaker, Lysann Sauer, Danielle Monteil, et al.
Scientific Reports|July 21, 2017
Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancerQi Wang, Heba Alshaker, Torsten Böhler, et al.
Cytokine|February 7, 2006
FK506, transforming growth factor-beta1 and mesangial matrix synthesis: parallels and differences compared with cyclosporine AJohannes Waiser, Kerstin Dell, Jan Kreutzkamp, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 29, 2002
Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cellsJohannes Waiser, Kerstin Dell, Torsten Böhler, et al.
Cytokine|April 29, 2008
Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patientsTorsten Böhler, Johannes Waiser, Steffi Lichter, et al.
Oncotarget|November 9, 2016
Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1Heba Alshaker, Qi Wang, Yoshiaki Kawano, et al.
Scientific Reports|June 16, 2017
Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1Heba Alshaker, Qi Wang, Torsten Böhler, et al.
Virchows Archiv : an International Journal of Pathology|June 19, 2002
Immunohistochemical double-staining of renal allograft tissue: critical assessment of three different protocolsJohannes Waiser, Stefan Schwaar, Torsten Böhler, et al.
Transplant Immunology|December 26, 2007
Tabebuia avellanedae extracts inhibit IL-2-independent T-lymphocyte activation and proliferationTorsten Böhler, Jochen Nolting, Purevtseren Gurragchaa, et al.
Clinical Transplantation|November 15, 2006
FTY720 (fingolimod) in renal transplantationKlemens Budde, Manuela Schütz, Petra Glander, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Advances in Cancer Research|January 8, 2013
Therapeutic potential of targeting SK1 in human cancersHeba Alshaker, Lysann Sauer, Danielle Monteil, et al.
Scientific Reports|July 21, 2017
Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancerQi Wang, Heba Alshaker, Torsten Böhler, et al.
Cytokine|February 7, 2006
FK506, transforming growth factor-beta1 and mesangial matrix synthesis: parallels and differences compared with cyclosporine AJohannes Waiser, Kerstin Dell, Jan Kreutzkamp, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 29, 2002
Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cellsJohannes Waiser, Kerstin Dell, Torsten Böhler, et al.
Cytokine|April 29, 2008
Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patientsTorsten Böhler, Johannes Waiser, Steffi Lichter, et al.
Oncotarget|November 9, 2016
Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1Heba Alshaker, Qi Wang, Yoshiaki Kawano, et al.
Scientific Reports|June 16, 2017
Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1Heba Alshaker, Qi Wang, Torsten Böhler, et al.
Virchows Archiv : an International Journal of Pathology|June 19, 2002
Immunohistochemical double-staining of renal allograft tissue: critical assessment of three different protocolsJohannes Waiser, Stefan Schwaar, Torsten Böhler, et al.
Transplant Immunology|December 26, 2007
Tabebuia avellanedae extracts inhibit IL-2-independent T-lymphocyte activation and proliferationTorsten Böhler, Jochen Nolting, Purevtseren Gurragchaa, et al.
Clinical Transplantation|November 15, 2006
FTY720 (fingolimod) in renal transplantationKlemens Budde, Manuela Schütz, Petra Glander, et al.
Pageof 4